BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BioCryst (Nasdaq: BCRX) announced on October 3, 2025 that its compensation committee granted inducement equity awards to eight newly hired employees.

The package includes 115,000 stock options and 91,450 restricted stock units (RSUs), granted effective October 1, 2025 under Nasdaq Listing Rule 5635(c)(4). Options carry an exercise price of $7.37 (closing price on the grant date), vest in four equal annual installments beginning one year after grant, and have a 10-year term. Awards are subject to the company’s Inducement Equity Incentive Plan and applicable award agreements.

News Market Reaction – BCRX

-2.46%

1 alert

-2.46% News Effect

On the day this news was published, BCRX declined 2.46%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees stock options to purchase an aggregate of 115,000 shares, and restricted stock units (RSUs) covering an aggregate of 91,450 shares, of BioCryst common stock. The options and RSUs were granted as of October 1, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $7.37 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO^® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
Investors:
investorrelations@biocryst.com 

Media:
media@biocryst.com 

FAQ

What inducement awards did BioCryst (BCRX) grant on October 1, 2025?

BioCryst granted 115,000 stock options and 91,450 RSUs to eight newly hired employees.

What is the exercise price of the BCRX options granted as inducements?

The options have an exercise price of $7.37 per share, equal to the closing price on the grant date.

When do the inducement options and RSUs for BCRX vest and expire?

They vest in four equal annual installments starting one year after grant; each option has a 10-year term.

Under which Nasdaq rule were the BioCryst inducement awards approved?

The awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement awards from BioCryst (BCRX)?

A total of eight newly hired employees received the awards.

Are the BCRX inducement awards subject to plan terms or agreements?

Yes. Awards are subject to the Inducement Equity Incentive Plan and applicable award agreements.